Table 1 Characteristics of the patients

	Sex	Age(years)	ANCA-V	Status	Chronology PF-ANCA-V	Follow-up (months)	Clinical	Type of PF	TLC/TLCO at diagnosis(%)	IAH	MPO-ANCAs	Eosinophils(×10⁹/l)	PF aggra-vation	Relapse of ANCA-V
1	F	78	MPA	Dead: CMV pneumonia	Same time	7	L K	NSIP	–	0	1	13	–	–
2	M	71	MPA	Dead: vasculitis	PF preceded ANCA-V	7	L K	ND	–	0	1	ND	–	–
3	M	77	MPA	Dead: exacerbation of ESRF	Same time	60	L N	ND	81/46	0	1	1.1	Yes	Yes
4	M	71	MPA	Dead: exacerbation of ESRF	Same time	37	L N S M	UIP	71/72	0	1	0.8	Yes	No
5	M	69	MPA	Dead: exacerbation of ESRF	Same time	67	L K N S	UIP	74/46	0	1	1.2	Yes	Yes
6	F	64	MPA	Alive	Same time	52	L N	UIP	101/87	0	1	0.6	Yes	No
7	M	69	MPA	Alive	Same time	92	L K M	UIP	78/62	0	1	4.4	Yes	No
8	M	70	MPA	Alive	PF preceded ANCA-V	18	L K N M	UIP	–	0	1	0.5	No	Yes
9	M	64	MPA	Alive	PF after ANCA-V	109	E L K S O	ND	–	0	1	0.2	No	Yes
10	F	75	WG	Alive	Same time	54	L	ND	–	0	1	ND	No	No
11	M	67	MPA	Alive	PF preceded ANCA-V	116	L K M N	UIP	45/51	0	1	<0.1	No	No
12	M	73	WG	Alive	Same time	63	E L K H	ND	–	0	1	0.2	No	No

ANCA-V, systemic vasculitis related to antineutrophil cytoplasmic antibodies; CMV, cytomegalovirus; E, ear–nose–throat; ESRF, end-stage respiratory failure; IAH, intra-alveolar haemorrhage; K, kidney; L, lung; M, muscles; MPA, microscopic polyangiitis; MPO-ANCAs, anti-myeloperoxidase-ANCAs; N, neuropathy; ND, not determined; NSIP, non-specific interstitial pneumonia; O, ophthalmology; PF, pulmonary fibrosis; S, skin; TLC, total lung capacity at diagnosis (%); TLCO, carbon monoxide transfer factor; UIP, usual interstitial pneumonia; WG, Wegener’s granulomatosis.